Cargando…

Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data

AIMS: Type 2 diabetes is a serious health challenge, and large-scale studies on its prevalence in Iran are lacking. In pharmacoepidemiology, case-finding can be done by reviewing the prescription databases for specific drug(s) prescribed for a disease. We aimed to determine the prevalence and incide...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirahmadizadeh, Alireza, Banihashemi, Sayed Aliakbar, Hashemi, Mehdi, Amiri, Sanaz, Basir, Suzan, Heiran, Alireza, Keshavarzian, Omid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213903/
https://www.ncbi.nlm.nih.gov/pubmed/34179534
http://dx.doi.org/10.1016/j.heliyon.2021.e07260
_version_ 1783709950870028288
author Mirahmadizadeh, Alireza
Banihashemi, Sayed Aliakbar
Hashemi, Mehdi
Amiri, Sanaz
Basir, Suzan
Heiran, Alireza
Keshavarzian, Omid
author_facet Mirahmadizadeh, Alireza
Banihashemi, Sayed Aliakbar
Hashemi, Mehdi
Amiri, Sanaz
Basir, Suzan
Heiran, Alireza
Keshavarzian, Omid
author_sort Mirahmadizadeh, Alireza
collection PubMed
description AIMS: Type 2 diabetes is a serious health challenge, and large-scale studies on its prevalence in Iran are lacking. In pharmacoepidemiology, case-finding can be done by reviewing the prescription databases for specific drug(s) prescribed for a disease. We aimed to determine the prevalence and incidence of type 2 diabetes in Fars province, Iran, using prescription data and a stepwise approach to ascertain the results. METHODS: A dataset of 3,113 insured individuals aged ≥35 years were selected. Their Prescription Data Centre records were reviewed for all drugs frequently used in controlling type 2 diabetes available in the Iranian pharmacopeia. Then we used a stepwise method for case-finding. In step one, each individual with a positive drug history for type 2 diabetes was labeled as an individual with diabetes. The next two steps were implemented for ascertainment of step one estimations. RESULTS: Prevalence of type 2 diabetes based on prescription, internist opinion, and phone call verification in 2015 and 2016 was 9.3% and 10.3%, 8.5% and 9.8%, and 7.2% and 8.7%, respectively. An incidence of 1.9% was determined for 2016. CONCLUSIONS: We obtained a realistic estimation of prevalence and incidence of treated type 2 diabetes, using prescription data which are large-scale, low cost, and real-time.
format Online
Article
Text
id pubmed-8213903
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82139032021-06-25 Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data Mirahmadizadeh, Alireza Banihashemi, Sayed Aliakbar Hashemi, Mehdi Amiri, Sanaz Basir, Suzan Heiran, Alireza Keshavarzian, Omid Heliyon Research Article AIMS: Type 2 diabetes is a serious health challenge, and large-scale studies on its prevalence in Iran are lacking. In pharmacoepidemiology, case-finding can be done by reviewing the prescription databases for specific drug(s) prescribed for a disease. We aimed to determine the prevalence and incidence of type 2 diabetes in Fars province, Iran, using prescription data and a stepwise approach to ascertain the results. METHODS: A dataset of 3,113 insured individuals aged ≥35 years were selected. Their Prescription Data Centre records were reviewed for all drugs frequently used in controlling type 2 diabetes available in the Iranian pharmacopeia. Then we used a stepwise method for case-finding. In step one, each individual with a positive drug history for type 2 diabetes was labeled as an individual with diabetes. The next two steps were implemented for ascertainment of step one estimations. RESULTS: Prevalence of type 2 diabetes based on prescription, internist opinion, and phone call verification in 2015 and 2016 was 9.3% and 10.3%, 8.5% and 9.8%, and 7.2% and 8.7%, respectively. An incidence of 1.9% was determined for 2016. CONCLUSIONS: We obtained a realistic estimation of prevalence and incidence of treated type 2 diabetes, using prescription data which are large-scale, low cost, and real-time. Elsevier 2021-06-09 /pmc/articles/PMC8213903/ /pubmed/34179534 http://dx.doi.org/10.1016/j.heliyon.2021.e07260 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Mirahmadizadeh, Alireza
Banihashemi, Sayed Aliakbar
Hashemi, Mehdi
Amiri, Sanaz
Basir, Suzan
Heiran, Alireza
Keshavarzian, Omid
Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data
title Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data
title_full Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data
title_fullStr Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data
title_full_unstemmed Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data
title_short Estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: A stepwise approach on Iranian data
title_sort estimating the prevalence and incidence of treated type 2 diabetes using prescription data as a proxy: a stepwise approach on iranian data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213903/
https://www.ncbi.nlm.nih.gov/pubmed/34179534
http://dx.doi.org/10.1016/j.heliyon.2021.e07260
work_keys_str_mv AT mirahmadizadehalireza estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata
AT banihashemisayedaliakbar estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata
AT hashemimehdi estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata
AT amirisanaz estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata
AT basirsuzan estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata
AT heiranalireza estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata
AT keshavarzianomid estimatingtheprevalenceandincidenceoftreatedtype2diabetesusingprescriptiondataasaproxyastepwiseapproachoniraniandata